Moving diagnostic frontiers in dermatology

Dermagnostix closes the gap in dermatology that has arisen between highly efficient therapeutics on the one hand and inadequate, antiquated diagnostic procedures on the other. This is achieved by molecular diagnostics on the basis of own protected IP. The company uses the LabDisk technology from Hahn-Schickard, a fully automated, microfluidic analysis system for point-of-care diagnostics. With PsorEx-LabDisk, the world's first molecular test to differentiate between psoriasis and eczema - diseases that affect almost 10% of the world population - will be launched.